Skip to main content
Top
Published in: International Journal of Hematology 4/2023

16-12-2022 | Retrovirus | Original Article

Clinical significance of human endogenous retrovirus K (HERV-K) in multiple myeloma progression

Authors: Yuta Masuda, Rei Ishihara, Yuki Murakami, Saki Watanabe, Yuta Asao, Nanami Gotoh, Tetsuhiro Kasamatsu, Hisashi Takei, Nobuhiko Kobayashi, Takayuki Saitoh, Hirokazu Murakami, Hiroshi Handa

Published in: International Journal of Hematology | Issue 4/2023

Login to get access

Abstract

Human endogenous retroviruses (HERVs) are retrotransposons that infect human germline cells and occupy 5–8% of the human genome. Their expression, though inhibited by mutation, deletion, and epigenetic mechanisms under normal conditions, is associated with diseases including cancer. This study aimed to clarify the association between HERVs and multiple myeloma (MM) progression. We found that HERV-K envelope (env) and long-term repeat (LTR) expression was statistically significantly higher within plasma cells in MM than in monoclonal gammopathy of undetermined significance or controls. HERV-K env knockdown increased proliferation in the MM.1S cell line and decreased the expression of the tumor suppressor genes TP53 and CDKN1A. TP53 and CDKN1A were highly expressed in MM, and their expression was correlated with HERV-K expression. HERV-K knockdown reduced apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3F, 3G, and 3H expression by 10–20% in MM.1S cells. The anti-retroviral agents nevirapine and nelfinavir suppressed proliferation and increased HERV-K expression in MM cell lines. Our results suggest that HERV-K is involved in MM progression, but its role is likely to go beyond promoting cell proliferation. Clarifying the role of HERV-K in MM will lead to the discovery of novel treatment strategies and supply new insights into MM pathogenesis.
Appendix
Available only for authorised users
Literature
3.
go back to reference Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241–9.CrossRefPubMedPubMedCentral Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241–9.CrossRefPubMedPubMedCentral
4.
go back to reference Belshaw R, Pereira V, Katzourakis A, Talbot G, Paces J, Burt A, et al. Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci USA. 2004;101:4894–9.CrossRefPubMedPubMedCentral Belshaw R, Pereira V, Katzourakis A, Talbot G, Paces J, Burt A, et al. Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci USA. 2004;101:4894–9.CrossRefPubMedPubMedCentral
5.
6.
go back to reference Zhao R, Chinai JM, Buhl S, Scandiuzzi L, Ray A, Jeon H, et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci USA. 2013;110:9879–84.CrossRefPubMedPubMedCentral Zhao R, Chinai JM, Buhl S, Scandiuzzi L, Ray A, Jeon H, et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci USA. 2013;110:9879–84.CrossRefPubMedPubMedCentral
8.
9.
go back to reference Salavatiha Z, Soleimani-Jelodar RS, Jalilvand S. The role of endogenous retroviruses-K in human cancer. Rev Med Virol. 2020;30:2142.CrossRef Salavatiha Z, Soleimani-Jelodar RS, Jalilvand S. The role of endogenous retroviruses-K in human cancer. Rev Med Virol. 2020;30:2142.CrossRef
10.
go back to reference Schmidt KLM, Vangsted AJ, Hansen B, Vogel UB, Hermansen NEU, Jensen SB, et al. Synergy of two human endogenous retroviruses in multiple myeloma. Leuk Res. 2015;39:1125–8.CrossRefPubMed Schmidt KLM, Vangsted AJ, Hansen B, Vogel UB, Hermansen NEU, Jensen SB, et al. Synergy of two human endogenous retroviruses in multiple myeloma. Leuk Res. 2015;39:1125–8.CrossRefPubMed
11.
go back to reference Nik ZS, Alexandrov LB, Wedge DC, Loo PV, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979–93.CrossRef Nik ZS, Alexandrov LB, Wedge DC, Loo PV, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979–93.CrossRef
12.
go back to reference Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003;424:94–8.CrossRefPubMedPubMedCentral Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003;424:94–8.CrossRefPubMedPubMedCentral
13.
go back to reference Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.CrossRefPubMed Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.CrossRefPubMed
14.
go back to reference Chaipan C, Smith JL, Hu WS, Pathak VK. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol. 2013;87:444–53.CrossRefPubMedPubMedCentral Chaipan C, Smith JL, Hu WS, Pathak VK. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol. 2013;87:444–53.CrossRefPubMedPubMedCentral
15.
go back to reference Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med. 2003;9:1404–7.CrossRefPubMed Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med. 2003;9:1404–7.CrossRefPubMed
16.
go back to reference Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, et al. Conserved footprints of APOBEC3G on hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol. 2008;82:8743–61.CrossRefPubMedPubMedCentral Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, et al. Conserved footprints of APOBEC3G on hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol. 2008;82:8743–61.CrossRefPubMedPubMedCentral
17.
18.
go back to reference Gills JJ, Lopiccolo JL, Tsurutani J, Shoemaker RH, Best CJM, Abu-Asab MS, et al. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007;13:5183–94.CrossRefPubMed Gills JJ, Lopiccolo JL, Tsurutani J, Shoemaker RH, Best CJM, Abu-Asab MS, et al. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007;13:5183–94.CrossRefPubMed
19.
go back to reference Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, et al. Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica. 2016;101:346–55.CrossRefPubMedPubMedCentral Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, et al. Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica. 2016;101:346–55.CrossRefPubMedPubMedCentral
20.
go back to reference Wang-Johanning FW, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, et al. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst. 2012;104:189–210.CrossRefPubMedPubMedCentral Wang-Johanning FW, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, et al. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst. 2012;104:189–210.CrossRefPubMedPubMedCentral
21.
go back to reference Li M, Radvanyi L, Yin B, Rycaj K, Li J, Chivukula R, et al. Downregulation of human endogenous retrovirus type K (HERV-K) viral env RNA in pancreatic cancer cells decreases cell proliferation and tumor growth. Clin Cancer Res. 2017;23:5892–911.CrossRefPubMedPubMedCentral Li M, Radvanyi L, Yin B, Rycaj K, Li J, Chivukula R, et al. Downregulation of human endogenous retrovirus type K (HERV-K) viral env RNA in pancreatic cancer cells decreases cell proliferation and tumor growth. Clin Cancer Res. 2017;23:5892–911.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical significance of human endogenous retrovirus K (HERV-K) in multiple myeloma progression
Authors
Yuta Masuda
Rei Ishihara
Yuki Murakami
Saki Watanabe
Yuta Asao
Nanami Gotoh
Tetsuhiro Kasamatsu
Hisashi Takei
Nobuhiko Kobayashi
Takayuki Saitoh
Hirokazu Murakami
Hiroshi Handa
Publication date
16-12-2022
Publisher
Springer Nature Singapore
Published in
International Journal of Hematology / Issue 4/2023
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-022-03513-7

Other articles of this Issue 4/2023

International Journal of Hematology 4/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine